Navigation Links
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Date:7/21/2009

SOUTH SAN FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company's lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration (FDA) to design this study, which is required for new chemical entities.

This study evaluated the cardiac safety of picoplatin by determining its effect on the cardiac QT/QTc interval by using time-matched pharmacokinetics and electrocardiograms (ECGs). A total of 45 patients with advanced solid malignancies received 150 mg/m2 picoplatin. The trial was conducted at seven clinical sites in the United States. Results showed no clinical cardiac-related events. In addition, no evidence of a clinically relevant trend in any ECG parameter was demonstrated.

"With these new picoplatin safety data, we continue to make progress toward our goal of initiating the filing in 2009 of a New Drug Application for picoplatin as a second-line treatment for small cell lung cancer, with approval and commercialization targeted for 2010," said Robert De Jager, M.D., chief medical officer of Poniard. "More than 1,100 cancer patients have received picoplatin in clinical studies to date. Additional safety and anticipated efficacy data from our ongoing Phase 3 SPEAR study will provide a strong database to support the NDA filing."

The Company plans to present data from the Phase 1 cardiac safety trial at a medical conference later this year.

About Picoplatin

Picoplatin is a new generation platinum-based chemotherapy agent that is in clinical dev
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... June 22, 2007 /PRNewswire/ -- MAP,Pharmaceuticals, Inc. today ... its Unit Dose Budesonide (UDB) pediatric asthma therapy,clinical ... Lutfi Kirdar,Convention and Exhibition Center in Istanbul, Turkey. ... and safety,of a novel submicron particle formulation of ...
... Announces Bioinformatics Partnership with,Illumina , BEYOND GENOME ... a leading developer of lab and data ... announced that,it has penned an agreement with ... participant in IlluminaConnect, a,bioinformatics software program established ...
Cached Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Oxygen", as it is known by researchers at the Norwegian ... is gained on the pitch thanks to their new system ... the Journal of Sports Medicine and has enjoyed ... improve the players, sprint, jump and endurance. , "With ...
... near manufacturing industries, a breath of air may ... location, finds a recent study involving a Kansas ... of geology at Kansas State University, along with ... School of Public Health and Department of Environmental ...
... Measurement of pressure within the eye, or intraocular pressure (IOP), ... in patients with glaucoma are believed to be related to ... to the optic nerve and vision. The clinical assessment ... daytime hours. In a new study, parents using the ...
... Steven Reinberg HealthDay Reporter , TUESDAY, March ... who have psychiatric disorders, especially post-traumatic stress disorder, are ... narcotic painkillers, a new study finds. Use of ... Vicodin, can become addictive and cause more serious problems, ...
... (HealthDay News) -- Most stroke patients undergo both CT and ... rising costs of stroke care in the United States, a ... from more than 600,000 patients diagnosed with stroke between 1999 ... of the patients who had MRI scans also had CT ...
... (HealthDay News) -- When it comes to wine, a new study ... on many consumers. The professionals seem to have a much ... State University explained. As a result, wine experts are able to ... people just can,t taste. "What we found is that the ...
Cached Medicine News:Health News:1 more 'player' on the pitch thanks to a new training method 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 3Health News:Home measurement of eye pressure in children may improve management of glaucoma 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: